Cytokine and lipid mediator blood concentrations after coronary artery surgery

Anesthesia and Analgesia

Volumn 85, Issue 6, 1997, Pages 1240-1246

  Nathan, Nathalie ^b   Denizot, Yves ^a   Cornu, Elisabeth ^c   Jauberteau, Marie Odile ^c   Chauvreau, Claude ^c   Feiss, P ^c  

^a UNIVERSITY OF LIMOGES   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CYTOKINE; INTERLEUKIN 8; THROMBOCYTE ACTIVATING FACTOR;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CORONARY ARTERY SURGERY; ENZYME INACTIVATION; EXTRACORPOREAL CIRCULATION; FEMALE; HEMOSTASIS; HUMAN; LIPID METABOLISM; LUNG INJURY; MALE; MEDIATOR RELEASE; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; COMPLEMENT SYSTEM PROTEINS; CORONARY ARTERY BYPASS; CREATINE KINASE; CYTOKINES; EXTRACORPOREAL CIRCULATION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKINS; LEUKOTRIENES; LIPIDS; LUNG DISEASES; MALE; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031424818     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199712000-00011     Document Type: Article

References (30)

1. Westaby S. Organ dysfunction after cardiopulmonary bypass: a systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med 1987;13:89-95.
2. Howard RJ, Crain C, Franzini DA, et al. Effects of cardiopulmonary bypass on pulmonary leukostasis and complement activation. Arch Surg 1988;123:1496-501.
3. Downing SW, Edmunds LH. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992;54:1236-43.
4. Kawamura T, Wakusawa R, Okada K, et al. Elevation of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin 8 and 6 in reperfusion injury. Can J Anaesth 1993;40:1016-21.
5. Kawamura T, Inada K, Okada H, et al. Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery. Can J Anaesth 1995;42:399-403.
6. Murray JF, Matthay MA, Luce JM, et al. An expanded definition of the acute respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3.
7. Fink PC, Romer M, Haeckel R, et al. Measurement of proteins with the Behring nephelometer: a multicenter evaluation. J Clin Chem Clin Biochem 1989;27:261-76.
8. Cazenave JP, Benveniste J, Mustard JF. Aggregation of rabbit platelets by platelet-activating factor is independant of the release reaction and the arachidonate pathway and inhibited by membrane active drugs. Lab Invest 1979;41:275-85.
9. Miwa M, Miyake T, Yamanaka T, et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 1988;82:1983-91.
10. Fujiwara T, Seo N, Murayama T, et al. Transient rise in serum cytokines during coronary artery bypass graft surgery. Eur Cytokine Netw 1997;8:61-6.
11. Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:1171-6.
12. Bates EJ. Eicosanoids, fatty acids and neutrophils: their relevance to the pathophysiology of disease. Prostaglandins Leukot Essent Fatty Acids 1995;53:75-86.
13. 2 receptor-specific antagonism in hypothermic cardiopulmonary bypass. Ann Thorac Surg 1994;57:999-1006.
14. Pinckard RN, Ludwig JC, McManus LM. Platelet-activating factors. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1988:139-73.
15. Wainwright CL, Parrait JR, Bigaud M. The effects of PAF antagonists on ischemia and reperfusion arrhythmias and ischaemia-induced platelet aggregation. Biomed Biochim Acta 1988;47:S224-7.
16. Ko W, Lang D, Hawes AS, et al. Platelet-activating factor antagonism attenuates platelet and neutrophil activation and reduces myocardial injury during coronary reperfusion. J Surg Res 1993;55:504-15.
17. Sawa Y, Shaper J, Roth M, et al. Platelet-activating factor plays an important role in reperfusion injury in myocardium. J Thorac Cardiovasc Surg 1994;108:953-9.
18. Straham ME, Graham RM, Eccleston DS, et al. Neutrophil platelet-activating factor production and acetylhydrolase activity in clinical acute myocardial infarction. Clin Exp Pharmacol Physiol 1995;22:102-6.
19. Zehr KJ, Poston RS, Lee PC, et al. Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass. Ann Thorac Surg 1995;59:328-35.
20. Nathan N, Mercury P, Denizot Y, et al. Effects of a PAF-receptor antagonist on hemodynamics during and after cardiopulmonary bypass. J Cardiothor Vasc Anesth 1995;9:647-52.
21. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995;374:549-53.
22. Graham RM, Srephens CJ, Stephens CJ, et al. Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care 1994;22:204-12.
23. Preiser JC, Schwartz D, Van der Linden P, et al. IL6 administration has no acute hemodynamic effect in the dog. Cytokine 1991;3:1-4.
24. Finkel MS, Oddis CV, Jacob TD, et al. Negative intropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
25. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the pro-inflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994;108:626-35.
26. Journois D, Pouard P, Greeley WJ, et al. Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Anesthesiology 1994;81:1181-9.
27. Detmers PA, Lo SK, Olsen-Egbert E, et al. Neutrophil-activating protein 1/interleukin-8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J Exp Med 1990;171:1155-62.
28. 2, prostacyclin and thromboxane changes during nonpulsatile cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 1986;91:858-66.
29. Starling MB, Neutze JM. Effects of Prostacyclin on cardiopulmonary bypass-mediated lung damage using extravascular lung water measurements. In: Advances in prostaglandin, thromboxane and leukotriene research. New York: Raven Press, 1987:1091-3.
30. Segiet W, Krieter H, Stieber C, et al. Effect of cyclooxygenase inhibition in a canine model of unilateral pulmonary occlusion and reperfusion. Intensive Care Med 1995;21:817-25.